Nearly two-thirds of foreign drug manufacturers and 38.9 percent of domestic facilities failed to submit FARs during the four-year period, the FDA’s Office of Pharmaceutical Quality found.
Although most of the sites handled non-sterile products, the missing FAR reports can include anything from a mislabeled batch to bacterial contamination.
The report did not specify which facilities failed to alert the FDA about potential safety problems.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
